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Background
Onchocerciasis (river blindness) is a human disease caused by
the filarial worm Onchocerca volvulus. Adult worms can live for over
a decade in skin nodules of affected humans, releasing millions of
microfilariae that cause debilitating itching and blindness [1]. An
estimated 37 million people are infected [2], and there are 46,000
new cases of blindness annually (http://www.apoc.bf/).
International programs supported by the World Health
Organization and many other groups have worked to control
the impact of onchocerciasis using vector control with insecticides
beginning in 1974 and mass drug administration (MDA) with
ivermectin (IVM, brand name Mectizan) beginning in 1987
(Figure 1) [3]. IVM is a highly effective microfilaricide and inhibits
female worm microfilarial production for several months. Annual
IVM MDA reduces morbidity [4,5] and lowers transmission [6,7].
From 1974 to 2002, the Onchocerciasis Control Programme
(OCP) in West Africa greatly decreased O. volvulus transmission in
the 11 OCP countries and prevented 600,000 cases of blindness
[8–10]. IVM without vector control has been the principal tool for
the Onchocerciasis Elimination Program of the Americas (1992–
present) [9] and the African Programme for Onchocerciasis
Control (1995–present). In the Americas, where O. volvulus is less
common, the Onchocerciasis Elimination Program has substan-
tially reduced transmission and is on track to eliminate the disease
[9].
The African Programme for Onchocerciasis Control has
extended treatment to 19 countries beyond those originally
included in the OCP through sustainable community-directed
IVM treatment [1,11]. By the end of 2005, 400 million treatments
had been supplied in Africa by Merck’s Mectizan Donation
Program, with an estimated 40 million people treated by nearly
300,000 community distributors (http://www.apoc.bf/). Never-
theless, the ecology of the disease in Africa, including the broad
geographic range of O. volvulus and its blackfly vector, leads to the
estimation that IVM treatment of at least 65% of the population
for 25 or more years will be necessary to eliminate infection [9,12].
There are significant logistical obstacles to achieving such
broad-ranging and prolonged treatment, and there is also concern
that O. volvulus resistance to IVM will emerge. IVM resistance
has become widespread in many parasitic nematodes of
livestock [13,14]. At present there are no alternative drugs for
IVM for use in the Onchocerca MDA programs that reduce
microfilariae or kill adult worms, which can live up to 15 years in
the human host.
The emergence of drug-resistant O. volvulus has been suggested
by reports of patients failing to respond to IVM treatment [15,16].
A recent report from Ghana has provided the first proof of IVM
resistance in O. volvulus: Mike Osei-Atweneboana and colleagues
showed that the ability of IVM to suppress skin microfilariae
repopulation was reduced in some communities that had received
6–18 years of IVM MDA [17]. The authors predict that a high
rate of repopulation of skin with microfilariae will allow continued
parasite transmission, possibly with IVM-resistant O. volvulus
leading to disease recrudescence. Additionally, studies have
associated IVM resistance with genetic markers [18–25],
particularly the b-tubulin gene in human O. volvulus and the
livestock nematode parasite Haemonchus contortus [22,26]. However,
previous O. volvulus genotyping studies were non-longitudinal,
using worms collected from different IVM-naı ¨ve and treated
individuals.
A New Study: IVM Causes Genetic Selection on
O. volvulus
A new study by Catherine Bourguinat and colleagues published
in PLoS Neglected Tropical Diseases extends these previous reports and
concludes not only that IVM causes genetic selection on O. volvulus
worms, but that this selection is also associated with a lower
reproductive rate of the female parasites [27]. In this study of O.
volvulus treatment in a hyperendemic region of central Cameroon,
parasite genotypes (b-tubulin gene and two controls) and pheno-
types (female fertility) were characterized in worms collected from
the same individuals before and after four or 13 IVM treatments
over three years. Parasites were collected pre- and post-treatment
from clinical trial patients in four IVM treatment groups: 150 mg/
kg of body weight annually or three-monthly, and 800 mg/kg
annually or three-monthly.
Analyses of the genetic polymorphism in parasites pre- and post-
treatment clearly showed a significant selection for b-tubulin
heterozygotes in female worms. The most marked effect was in
the three-monthly treated groups, where the frequency of the b-
tubulin ‘‘aa’’ homozygotes post-IVM was reduced on average from
68.6% to 25.6%, while the ‘‘ab’’ heterozygotes increased from
20.9% to 69.2% over three years. Moreover, b-tubulin ‘‘aa’’
homozygous females were significantly more fertile than hetero-
zygotes before treatment (67% versus 37%) and 12 months
after the last IVM dose in the groups treated annually (60%
versus 17%). No significant selection was observed in the control
genes.
Citation: Lustigman S, McCarter JP (2007) Ivermectin Resistance in Onchocerca
volvulus: Toward a Genetic Basis. PLoS Negl Trop Dis 1(1): e76. doi:10.1371/journal.
pntd.0000076
Received July 17, 2007; Accepted August 1, 2007; Published August 30, 2007
Copyright:  2007 Lustigman, McCarter. This is an open-access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
Funding: The authors received no specific funding for this study.
Competing Interests: SL has received research grants for the development of
anti-Onchocerca vaccines and macrofilaricides. JPM is a share-holder and
employee of Divergence, Inc., a company that works on parasite control in
plants, animals, and humans.
*E-mail: slustigman@nybloodcenter.org
PLoS Neglected Tropical Diseases | www.plosntds.org 1 2007 | Volume 1 | Issue 1 | e76Strengths and Limitations of the Study
A major strength of this study is that the O. volvulus parasites
were collected from the same individuals before and after IVM
treatments. Therefore the observed changes in genotype frequen-
cies between IVM-naı ¨ve and treated O. volvulus populations are not
due to factors such as geographical or sampling effects.
The main limitation of this study was that some worm samples
could not be genotyped, thus reducing the number that could be
analyzed, particularly after treatment. This limitation might also
have impeded the genotyping of DNA, ideally prepared from
worm sections instead of just whole females. What is given as
a single genotype is, in fact, a consensus of multiple genotypes
including the adult female body and progeny (uterine embryos and
microfilariae). Furthermore, the samples from unfertile females,
which probably represent true singletons, were treated the same as
those from females classified as being of low or high fertility.
Consequently, the study leaves unanswered questions including
whether the selection of the b-tubulin heterozygote genotypes is on
the females or their progeny. If it is on the progeny, questions
remain regarding the fitness and susceptibility to IVM treatment
of the b-tubulin heterozygote microfilariae once they develop into
the infective stage larvae and enter a new human host.
The authors do not present a hypothesis to explain why IVM
causes selection for b-tubulin heterozygote genotypes. The
glutamate-gated chloride channels are thought to be involved in
the mode of action of IVM and resistance to the drug [28].
Treatment with IVM is known to cause a loss of polymorphism
not only at certain b-tubulin gene loci, but also at certain loci of the
genes encoding the gamma-aminobutyric acid receptor, gluta-
mate-gated chloride channel, and ATP-binding cassette trans-
porter of IVM-resistant H. contortus [23]. It will therefore be
important to examine for polymorphisms in these genes in the
uniquely collected O. volvulus female worms described in this study
and in future studies.
Despite these caveats, the study indicates that IVM causes
genetic selection on O. volvulus worms and points to the daunting
possibility of the spread of IVM-resistant parasites in endemic
regions that have been treated with IVM.
Implications of the Study for River Blindness
Control
The finding that IVM treatment selected for b-tubulin hetero-
zygotes and that this selection was dependent on dosage raises
important concerns for the current river blindness control
programs. These concerns are heightened by the fact that this
gene has been linked with IVM resistance in another parasitic
nematode [26], and by the recent evidence that IVM resistance is
occurring in O. volvulus [17]. Semiannual or more frequent
treatments are ongoing in some endemic areas and are under
consideration in other areas. Such treatment might increase the
selection pressure. Therefore, Bourguinat and colleagues’ study is
a wake-up call for control programs to select their treatment
regimens carefully and to develop plans for detecting IVM
resistance and the associated genetic markers (control programs
will require additional funding for these plans). This study presents
a possible structure of study design that will incorporate the
detection and validation of the genetic markers associated with
IVM resistance.
Simultaneously, we need to greatly increase our current level of
effort and support to develop and test a new generation of control
tools for onchocerciasis. These tools should include both vaccines
and macrofilaricides (drugs which kill adult worms) that have new
Figure 1. Distribution of Onchocerciasis Showing Current Status of Global Onchocerciasis Control. Red shading represents areas
receiving ivermectin treatment. Yellow shading represents areas requiring further epidemiological surveys. Green shading indicates the area covered
by the OCP in West Africa. Pink zones indicate the special intervention zones, i.e., previous OCP areas receiving ivermectin and some vector control.
Figure from [10].
doi:10.1371/journal.pntd.0000076.g001
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throughs now make macrofilaricide development more feasible,
and accordingly such development is now a high-priority goal with
the World Health Organization’s Special Programme for Re-
search and Training in Tropical Diseases and the Bill and Melinda
Gates Foundation [29,30]. The development of an anti-Onchocerca
vaccine has been the focus of research supported by the Edna
McConnell Clark Foundation [31]. It may be possible to link such
a vaccine with drug treatments in a program of vaccine-linked
chemotherapy [32,33]. These new generations of control tools
would complement the present control measure—the establish-
ment of sustainable community-directed treatment with IVM—
and ultimately support the long-term goal of eliminating
onchocerciasis as a public health problem in Sub-Saharan Africa.
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